变体rs7665090与多发性硬化症患者的干扰素-β反应有关
Andreu Vilaseca1, Elena Urcelay2, Sunny Malhotra1
1Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
European journal of neurology
|July 16, 2025
概括
rs7665090基因变异与多发性硬化症 (MS) 患者对干扰素-β (IFNβ) 治疗的更好反应有关. 基因定型这种多态可能有助于个性化MS治疗策略,以改善结果.
科学领域:
- 神经免疫学 神经免疫学
- 药物遗传学 药物遗传学
- 多发性硬化症的治疗方法
背景情况:
- 多发性硬化症 (MS) 患者的rs7665090风险变体的GG基因型与T细胞中核因子kappa B (NFκB) 活性增强有关.
- 了解遗传多态度对治疗反应的影响对于优化多发性硬化症管理至关重要.
研究的目的:
- 调查rs7665090多态和多种疾病修饰疗法 (DMT) 对多发性硬化症 (MS) 患者的治疗反应之间的关联.
- 要确定rs7665090基因型是否可以预测MS的治疗疗效.
主要方法:
- 在558名多发性硬化症患者的rs7665090多态性基因定型,这些患者接受了不同类型的DMT治疗,包括注射 (IFNβ,glatiramer acetate),口服 (dimethylfumarate, teriflunomide,fingolimod) 和natalizumab.
- 治疗反应在1-2年后使用临床和放射性结果 (里约评分,EDSS,MRI) 进行评估.
- 使用统计分析,包括单变量和多变量逻辑回归来评估基于基因型的治疗反应.
主要成果:
- 对于rs7665090的GG同性与接受干扰素-β (IFNβ) 治疗的MS患者的良好治疗反应有显著的相关性 (OR 0.42;p=0.037).
- 这种关联是IFNβ治疗的特异性,并没有扩展到研究中评估的其他DMT.
- rs7665090多态性似乎是一个预测IFNβ响应的生物标志物在MS患者的一个子集.
结论:
- rs7665090多态性作为一种预测生物标志物,用于在多发性硬化症 (MS) 中对干扰素-β (IFNβ) 治疗的良好反应.
- 基因定型rs7665090可以帮助临床医生识别最有可能从IFNβ治疗中受益的MS患者.
- 建议在更大的患者队伍中进行进一步验证,以确认这些发现及其临床实用性.
更多相关视频
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
13.5K
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.2K
相关概念视频
01:05Single Nucleotide Polymorphisms-SNPs
15.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.9K
01:11Genome-wide Association Studies-GWAS
14.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.3K